01PePeptidesENHANCED

Semaglutide available at Ascension Peptides — Save 50% with code ENHANCED

Buy Semaglutide
TrendingCOA VerifiedInjectable

Semaglutide

GLP-1 receptor agonist for blood sugar management and weight reduction research

Half-life

~7 days

Typical Dose

0.25-2.4mg weekly

Format

Injectable

Purity

≥99%

Buy from Ascension — 50% off code ENHANCEDRead research

Overview

Semaglutide is a GLP-1 receptor agonist marketed as Ozempic and Wegovy [5]. It revolutionized weight management research with ~15% average body weight reduction at 68 weeks in the STEP-1 trial [1]. The SELECT trial demonstrated cardiovascular event reduction in adults with obesity without diabetes [2], and long-term cardiovascular safety was established earlier in SUSTAIN-6 [4]. It remains the most prescribed weight loss medication globally [9].

Mechanism

GLP-1 receptor agonist that mimics the incretin hormone [5,6]. Slows gastric emptying, reduces appetite via central GLP-1 receptors in the hypothalamus, and increases glucose-dependent insulin secretion [7]. A C18 fatty acid side chain enables albumin binding for the ~7-day half-life [5]. Effects on reward circuitry and food preference have also been documented [8].

Researched benefits

  • ~15% average weight reduction at 68 weeks
  • Improved glycemic control
  • Reduced cardiovascular events (SELECT trial)
  • Once-weekly dosing
  • Extensive safety data

Frequently asked

How long until results are visible?

Most subjects show measurable weight reduction within 8-12 weeks at therapeutic doses, with continued reduction over 6-12 months. Maximum response in STEP trials was reached around month 16-18 at the 2.4mg dose.

What's the half-life of Semaglutide?

Approximately 7 days, the longest of the major GLP-1 agonists. This is achieved through a fatty acid side chain that binds albumin, slowing renal clearance and enabling once-weekly dosing.

What's the typical research dose escalation?

Standard titration starts at 0.25mg weekly for 4 weeks, then doubles every 4 weeks: 0.5mg, 1mg, 1.7mg, and finally 2.4mg for weight management. Slow escalation is critical to mitigate nausea.

Subcutaneous vs intramuscular for Semaglutide?

Subcutaneous is the only validated route. Pharmacokinetic profile and trial data are based on SC administration in abdomen, thigh, or upper arm. IM injection is not studied and not recommended.

How is Semaglutide reconstituted?

For a 5mg vial, 1.25mL of bacteriostatic water yields 4mg/mL (or 0.25mg per 0.0625mL). Add diluent slowly, swirl — never shake. Refrigerate at 2-8°C and use within 28-56 days depending on preservative.

Are there contraindications in research?

Boxed warning for thyroid C-cell tumors (rodent data). Contraindicated with personal/family history of MTC or MEN 2. Caution with pancreatitis history, gallbladder disease, severe GI disease, and diabetic retinopathy.

Scientific Literature

References

  1. [1]

    Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    New England Journal of Medicine · PubMed: 33567185

  2. [2]

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

    New England Journal of Medicine · PubMed: 37952131

  3. [3]

    Davies M, Færch L, Jeppesen OK, et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).

    The Lancet · PubMed: 33667417

  4. [4]

    Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

    New England Journal of Medicine · PubMed: 27633186

  5. [5]

    Knudsen LB, Lau J. (2019). The Discovery and Development of Liraglutide and Semaglutide.

    Frontiers in Endocrinology · PubMed: 31040829

  6. [6]

    Drucker DJ. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1.

    Cell Metabolism · PubMed: 29320702

  7. [7]

    Gabery S, Salinas CG, Paulsen SJ, et al. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways.

    JCI Insight · PubMed: 32213704

  8. [8]

    Blundell J, Finlayson G, Axelsen M, et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight.

    Diabetes, Obesity and Metabolism · PubMed: 28371177

  9. [9]

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF).

    New England Journal of Medicine · PubMed: 37622681

  10. [10]

    Rubino DM, Greenway FL, Khalid U, et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity (STEP 8).

    JAMA · PubMed: 35015037

  11. [11]

    Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW).

    New England Journal of Medicine · PubMed: 38785209

  12. [12]

    Wadden TA, Bailey TS, Billings LK, et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3).

    JAMA · PubMed: 33591366

Citations are provided for educational purposes. Always verify primary sources before drawing research conclusions.

Ready to start your research

Get Semaglutide from Ascension Peptides

COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.

Buy Semaglutide now